scholarly journals Sinonasal Tract Solitary Fibrous Tumor: A Clinicopathologic Study of Six Cases with a Comprehensive Review of the Literature

2017 ◽  
Vol 12 (4) ◽  
pp. 471-480 ◽  
Author(s):  
Lester D. R. Thompson ◽  
Sean K. Lau
2003 ◽  
Vol 48 (5) ◽  
pp. 544-554 ◽  
Author(s):  
Subramanian Krishnakumar ◽  
Nirmala Subramanian ◽  
E.Ravindra Mohan ◽  
Lakshmi Mahesh ◽  
Jyotirmay Biswas ◽  
...  

2019 ◽  
Vol 13 (4) ◽  
pp. 597-605 ◽  
Author(s):  
Lester D. R. Thompson ◽  
Christina Wei ◽  
Lisa M. Rooper ◽  
Sean K. Lau

In Vivo ◽  
2020 ◽  
Vol 34 (6) ◽  
pp. 3649-3654
Author(s):  
MIZUHO MITAMURA ◽  
SATORU KASE ◽  
YASUO SUZUKI ◽  
TAKATOSHI SAKAGUCHI ◽  
YUKA SUIMON ◽  
...  

1992 ◽  
Vol 6 (4) ◽  
pp. 135-137 ◽  
Author(s):  
Ari Namon

Nonepithilial tumors of the nasal cavity, paranasal sinuses, and nasopharynx are uncommon. Awareness of the variety of tumors to be found and their distinguishing characteristics allows for proper diagnosis and treatment. We present a case of solitary fibrous tumor of the sinonasal tract with a discussion of its differential diagnosis, evaluation, and treatment.


2021 ◽  
Vol 149 ◽  
pp. e345-e359
Author(s):  
Sricharan Gopakumar ◽  
Visish M. Srinivasan ◽  
Caroline C. Hadley ◽  
Adrish Anand ◽  
Marc Daou ◽  
...  

2011 ◽  
Vol 154 (2) ◽  
pp. 237-248 ◽  
Author(s):  
Hong Chen ◽  
Xian-Wei Zeng ◽  
Jin-Song Wu ◽  
Ya-Fang Dou ◽  
Yin Wang ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2913
Author(s):  
Javier Martin-Broto ◽  
Jose L. Mondaza-Hernandez ◽  
David S. Moura ◽  
Nadia Hindi

Solitary fibrous tumor (SFT) is a rare mesenchymal, ubiquitous tumor, with an incidence of 1 new case/million people/year. In the 2020 WHO classification, risk stratification models were recommended as a better tool to determine prognosis in SFT, to the detriment of “typical” or “malignant” classic terms. The risk for metastasis is up to 35–45%, or even greater, in series with a longer follow-up. Over the last few decades, advances in immunohistochemistry and molecular diagnostics identified STAT6 nuclear protein expression and the NAB2–STAT6 fusion gene as more precise tools for SFT diagnosis. Recent evidence taken from retrospective series and from two prospective phase II clinical trials showed that antiangiogenics are active and their sequential use from first line should be considered, except for dedifferentiated SFT for which chemotherapy is the best option. Since the fusion transcript driver’s first description in 2013, new insights have been brought on key molecular events in SFT. This comprehensive review mainly focuses on the superior efficacy of antiangiogenics over chemotherapeutic agents in SFT, provides the current knowledge of key molecules that could co-drive the SFT behavior, and suggests new target candidates that deserve to be explored in preclinical and clinical research in SFT.


2021 ◽  
Vol 1 (4) ◽  
pp. 731
Author(s):  
Deepsekhar Das ◽  
Sahil Agrawal ◽  
Aishwarya Rathod ◽  
Sujeeth Modaboyina ◽  
Seema Sen ◽  
...  

2008 ◽  
Vol 14 (2) ◽  
pp. 213-217 ◽  
Author(s):  
Giuseppe Leoncini ◽  
Vincenza Maio ◽  
Marco Puccioni ◽  
Alessandro Franchi ◽  
Vincenzo De Giorgi ◽  
...  

2016 ◽  
Vol 2 (2) ◽  
pp. 42-44
Author(s):  
S Parinita ◽  
KN Mohan Rao ◽  
Vivek LNU

ABSTRACT Localized fibrous tumors of the lung arise from the visceral pleura and are pedunculated. They also project into the pleural cavity. The tumor with an entirely pulmonary location is extremely rare. We present here a rare case of intrapulmonary localized fibrous tumor with review of the literature. How to cite this article Parinita S, Rao KNM, Vivek. Intrapulmonary Solitary Fibrous Tumor of the Lung: A Rare Case Presentation. J Med Sci 2016;2(2):42-44.


Sign in / Sign up

Export Citation Format

Share Document